Result of Extraordinary General Meeting
Updated : 11:25
Syncona Limited
Result of Extraordinary General Meeting
30 October 2018
At the Extraordinary General Meeting ("EGM") held on 30 October 2018, the resolution as set out in the Notice of EGM dated 4 October 2018 was duly passed.
Details of the proxy voting results on the resolution proposed at the EGM were as follows.
Special Resolution | For | Against | Withheld | Discretion |
That the proposed changes to the Company's Investment Policy as set out in Part 2 of the circular to Shareholders dated 4 October 2018, of which this notice forms part, are approved. | 429,265,432 | 10,774 | 2,573 | 0 |
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
The revised Investment Policy set out in the circular to Shareholders has accordingly been approved and is now effective.
In accordance with the Listing Rule 9.6.2, a copy of the special resolution passed has been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
A copy of the circular to Shareholders is available on the Company's website at www.synconaltd.com/investors/document-library.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2010
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.